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ABSTRACT 
Diet1 modulates intestinal production of the hormone fibroblast growth factor 15 (FGF15), 
which signals in liver to regulate bile acid synthesis. C57BL/6ByJ mice with a spontaneous 
Diet1 null mutation are resistant to hypercholesterolemia compared to wild-type C57BL/6J mice 
through enhanced cholesterol conversion to bile acids. To further characterize the role of Diet1 
in metabolism, we generated Diet1–/– mice on the C57BL6/J genetic background. C57BL/6J 
Diet1–/– mice had elevated bile acid levels, reduced Fgf15 expression, and increased 
gastrointestinal motility and intestinal luminal water content, which are symptoms of bile acid 
diarrhea (BAD) in humans. Natural genetic variation in Diet1 mRNA expression levels across 76 
inbred mouse strains correlated positively with Ffg15 mRNA and negatively with serum bile 
acid levels. This led us to investigate the role of DIET1 genetic variation in primary BAD 
patients. We identified a DIET1 coding variant (rs12256835) that had skewed prevalence 
between BAD cases and controls. This variant causes an H1721Q amino acid substitution that 
increases the levels of FGF19 protein secreted from cultured cells. We propose that genetic 
variation in DIET1 may be a determinant of FGF19 secretion levels, and may affect bile acid 
metabolism in both physiological and pathological conditions.  
 
 
Supplementary key words: intestine • diarrhea • fibroblast growth factor 15/19 • hybrid mouse 
diversity panel
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INTRODUCTION 
Cholesterol is eliminated from the body through the catabolism of cholesterol to bile acids, and 
subsequent loss of bile acids in the feces (1-3). The elimination of bile acids through the intestine 
is the basis for the reduction of serum cholesterol levels through the use of bile acid binding 
resins, which sequester bile acids in the intestine to form an insoluble complex (4-6). More 
recently, we identified a mutant mouse model that exhibits constitutive conversion of cholesterol 
to bile acids and elimination through feces and urine, leading to resistance to dietary cholesterol 
(7, 8). The underlying mutation occurs in the Diet1/Malrd1 gene, which encodes a 236 kD 
protein that is expressed exclusively in epithelial cells lining the small intestinal villi and kidney 
proximal tubules (7). Since Diet1 is the original gene name and all studies published thus far use 
Diet1, we will continue to use this designation here. Diet1 influences enterohepatic signaling 
between small intestine and liver to modulate hepatic bile acid synthesis. Specifically, Diet1 
deficiency leads to reduced production and/or secretion by enterocytes of the hormone fibroblast 
growth factor (FGF) 15 (FGF19 in humans) (7). FGF 15/19 is secreted by the ileum into the 
enterohepatic circulation, and down-regulates bile acid synthesis by signaling through hepatic 
co-receptors (fibroblast growth factor receptor 4 and β klotho) (2, 9-11).  
The augmentation of flux through the bile acid synthetic pathway has been successfully 
used therapeutically to control plasma cholesterol levels (2, 12, 13). However, the amount of bile 
acids lost through excretion must be carefully regulated, as increased bile acid levels in the 
intestine can trigger the flow of water into the colon, resulting in bile acid malabsorption, also 
known as bile acid diarrhea (BAD) (2, 14).  One of the mechanisms by which elevated intestinal 
bile acids may influence severity of BAD is by increasing colonic motility (15, 16). BAD may be 
classified into three types based on distinct etiologies (15). Type 1 BAD was first recognized in 
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association with surgical resection or disease of the terminal ileum, which leads to impaired 
reabsorption of bile acids from the intestinal lumen (17). This results in elevated fecal bile acid 
levels and is treated with bile acid sequestrants (18). Type 2 BAD (referred to herein as “primary 
BAD”) was recognized in 1976 as a similar syndrome without obvious ileal disease (19). 
Primary BAD appears to be heterogeneous in etiology (20-22). Type 3 BAD encompasses 
chronic diarrheas caused by other conditions that can affect bile acid absorption, such as 
cholecystectomy or bacterial overgrowth in the small intestine (23). 
 Primary BAD is the most common of the bile acid malabsorption syndromes, estimated 
to affect about 1% of the European population, and accounting for about 30% of cases with 
chronic diarrhea and diarrhea-predominant irritable bowel syndrome (24). The definitive test for 
primary BAD is the measurement of fecal bile acid levels, but this is demanding and not usually 
performed clinically. Alternatively, BAD may be defined by administering a radiolabeled bile 
acid (selenium homocholic acid taurine, SeHCAT), and determining the amount retained in the 
body after 7 days (25, 26). Patients with primary BAD eliminate the radiolabel more rapidly than 
controls, as determined by scanning with a gamma camera (25). This test is available in Europe, 
but not in the United States. An additional screening method for BAD is the quantification of the 
bile acid synthetic intermediate C4 (7α-hydroxy-cholest-4-ene-3-one), which is inversely 
correlated with SeHCAT retention (27). 
A relationship between BAD and FGF19 levels has been identified by Walters and 
colleagues. BAD patients were diagnosed by reduced SeHCAT retention in the absence of bile 
acid sequestrants. In BAD patients, FGF19 levels were lower than normal and there was a 
positive correlation between FGF19 and percent SeHCAT retention (28). There was also an 
inverse relationship between FGF19 and C4 levels (16, 29).  
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Animal studies provide independent support for a key role of FGF15/19 in bile acid 
homeostasis. In monkeys, administration of anti-FGF19 antibodies produced severe bile acid loss 
and diarrhea (30). Furthermore, mice carrying a knockout mutation for FGF15 exhibited excess 
fecal bile acid secretion as observed in humans (31). As described earlier, Diet1-deficient mice 
exhibit very low levels of FGF15 in the small intestine, and exhibit constitutive up-regulation of 
hepatic bile acid synthesis (7). Providing FGF15 to Diet1–deficient mice led to normalization of 
bile acid synthetic gene expression, demonstrating that Diet1 functions upstream of FGF15 to 
modulate bile acid levels (7).  
In the current study, we characterize the effects of mouse Diet1 null mutation on an 
isogenic C57BL/6J background and find that these mice experience traits reminiscent of BAD in 
humans. We further assess whether natural genetic variation in Diet1 expression across more 
than six-dozen inbred mouse strains is correlated with Fgf15 expression and bile acid traits. We 
expand our investigation to evaluate the presence of functional DIET1 variants in humans, and 
characterize a non-synonymous coding variant that has a significantly different prevalence in 
control and BAD subjects, and which influences FGF19 levels secreted from cultured cells.  
These studies expand our knowledge of the role of variation in Diet1 levels and sequence in traits 
associated with bile acid metabolism.  
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MATERIALS AND METHODS  
Diet1–/– congenic mice. C57BL/6J and C57BL/6ByJ mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME). Diet1–/– congenic mice were generated by backcrossing the Diet1 
allele from C57BL/6ByJ mice onto the C57BL/6J background for 8 generations. The Diet1 allele 
was genotyped using PCR primers specific for the mutant and wild-type alleles as described 
previously (7). Heterozygous mice from the N8 backcross generation were intercrossed to 
produce wild-type (Diet1+/+) and Diet1–/– mice. Mice were placed on an atherogenic diet 
(TD88051, Harlan Laboratories, WI) as previously described (7) for 3 or 6 weeks before tissues 
were collected. All mouse studies were conducted in accordance with, and approved by, the 
Institutional Animal Research Committee of the University of California, Los Angeles. 
Mouse plasma lipid and bile acid measurements. Mice were fasted 16 hr and blood was 
collected under isoflurane anesthesia from the retro-orbital sinus. Enzymatic assays for total 
cholesterol and HDL-cholesterol were performed as described (32). Total bile acid levels were 
assessed using Diazyme Total Bile Acids Assay Kit (DZ042A-K, Diazyme Laboratories, Poway, 
CA).  
Hybrid Mouse Diversity Panel (HMDP) analysis. The HMDP strains have been described 
previously (33). Briefly, 76 inbred and recombinant inbred mouse strains (3-5 mice/strain) were 
assessed at 8 weeks for gene expression in ileum for Diet1 and Fgf15. Biliary bile acid and 
cholesterol levels were determined by calorimetric assays from Diazyme and ThermoFisher 
(A12216, ThermoFisher Scientific, Grand Island NY), respectively. Correlation analyses were 
performed in Graphpad Prism (v7).  
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Gene expression and quantitative-PCR. Liver and small intestine isolated from mice following 
a 16-hr fast and RNA was prepared using Trizol (Invitrogen). Primer sequences for qPCR of 
Diet1, Fgf15, Asbt, Cyp7a1, Cyp8b1, Cyp27, Fgfr4, and B2m (as a normalization gene) were 
reported previously (7). Rpl4 primer sequences were 5’gatgagctgtatggcacttgg’3 for forward and 
5’cttgtgcatgggcaggtt’3 for reverse primer. 
Determination of gastrointestinal transit time. Mice were fed atherogenic diet for 2 weeks. 
After an overnight fast with ad libitum water, mice were gavaged with a semiliquid solution (0.2 
mL) of 5% Evans blue and 1.5% methylcellulose, as previously described (34).  Mice were 
continuously monitored and the time to produce the initial fecal pellet was determined as a 
measure of gastrointestinal transit time.  
Intestinal water content. Mice were fasted 18-hours with ad libitum water and refed for three 
hours with atherogenic diet. The small intestine and colon were excised precisely and the 
contents collected by gentle extrusion. Contents were weighed, desiccated for 3 days, and then 
weighed again to determine the fluid and solid weights as described previously (35-37). Weights 
of the water and dry intestinal contents were expressed as absolute amounts, and after 
normalization to intestinal lengths. 
Study subjects. Genomic DNA was studied in an initial cohort of 44 subjects that has been 
described before (38) (Table 1). 22 of the subjects had chronic diarrhea due to primary BAD, 
with SeHCAT 7d retention between 1 and 7%. The control group of 22 subjects had normal 
bowel habits and no evidence of malabsorption. Both groups were of predominantly Caucasian 
origin with no subjects of African descent. The DNA samples were obtained under the approval 
of the local Research Ethics Committees (Institutional Review Boards) of Hammersmith, Queen 
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Charlotte’s & Chelsea and Acton, and Wrightington, Wigan and Leigh Hospitals. Informed 
consent was obtained from all subjects. The DNA was sequenced under a protocol approved by 
the UCLA Institutional Review Board. 
 Genomic DNA was also studied in an additional cohort of patients, who have also been 
previously described (28) (Table 1). This cohort consisted of a prospectively recruited set of 78 
patients with chronic diarrhea who underwent SeHCAT testing and FGF19 measurements. This 
cohort was also predominantly Caucasian in origin.  
DIET1 sequencing. The exons and flanking intron sequences of DIET1 were amplified by PCR 
using oligonucleotide primer sequences listed in Supplemental Table 1. PCR products were 
treated with recombinant exonuclease I and shrimp alkaline phosphatase (Agilent Technologies, 
Santa Clara, CA), and sequenced on a Biosystems 3730 Capillary DNA Analyzer using BigDye 
terminator cycle sequencing reagents. Variants were confirmed by amplification of an 
independent PCR product and sequencing both strands. 
rs12256835 genotyping. Genomic DNA was extracted from patient blood using QiAmp DNA 
mini kit (Qiagen, Manchester, UK) according to the manufacturer’s protocols. Samples were 
genotyped for the rs12256835 variant using a TaqMan allelic discrimination assay (Life 
Sciences, Paisley, UK). PCR was performed on 96 well reaction plates and analyzed using a 
StepOnePlus RT-PCR machine (Life Sciences) to obtain an allelic discrimination plot including 
a negative water control. Reaction volume was 15µl per well including 7.5µl TaqMan 
genotyping Master Mix (2X), 0.375µl SNP Assay mix (40X), 6.125 nuclease free water and 1µl 
genomic DNA. Standard PCR conditions were: 95ºC for 10 minutes, followed by 40 cycles of 
amplification at 95ºC for 15 seconds and 60ºC for 1minute, followed by 60ºC for 30 seconds. 
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Serum FGF19 measurements. Serum FGF19 levels were measured by commercial ELISA 
assay (FGF19 Quantikine ELISA, R&D Systems, Minneapolis, MN) as previously described. 
100 µl aliquots of serum were assayed in duplicate according to the manufacturer’s protocols.  
Expression constructs and site-directed mutagenesis. Expression plasmids for human Diet1–
V5 and FGF19–Myc were generated previously (7). Site-directed mutagenesis was performed on 
the plasmid expressing Diet1–1721H to generate Diet1–1721Q using the QuikChange II XL 
Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) with primers 
gaagctcactgtgcacagtatacaagcacaacag (hDIET1_H1721Q-F) and 
ctgttgtgcttgtatactgtgcacagtgagcttc (hDIET1_H1721Q-R). Site-directed mutagenesis performed 
on the plasmid expressing Diet1–1712D to generate Diet1–1721G using primers 
cataagccagattgctctggtaggtctgatgaagc (hDIET1_H1712G-F) and 
gcttcatcagacctaccagagcaatctggcttatag (hDIET1_H1712G-R). 
FGF19 secretion assay. The effect of Diet1 on FGF19 secretion was assessed as previously 
described (7). Briefly, HEK293T cells (American Type Culture Collection, Manassas, VA) were 
transfected (in triplicate or quadruplicate) with pcDNA6 expression plasmids for FGF19-myc in 
combination with a V5-tagged control gene construct (Kdm5c), Diet1–1721H, Diet1–1721Q, 
Diet1–1712D, or Diet1–1712G (BioT Transfection Reagent, Bioland, Paramount, CA). After 24 
hours, an equal amount of fresh medium was added to each well. The following day, culture 
medium was collected to quantify the levels of FGF19 secreted in 24 hours, and cells were 
collected to quantify cellular FGF19 and Diet1 protein levels by Western blot. Diet1 was 
detected with rabbit anti-V5 (1:5000, Bethyl Laboratories, Montgomery, TX), FGF19 was 
detected with rabbit anti-Myc (1:10,000, Bethyl Laboratories, Montgomery, TX), and β-actin 
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was detected with a mouse monoclonal antibody (1:10,000, Sigma, St. Louis, MO). After 
secondary antibody application, protein bands were detected with ECL2 chemiluminescent 
reagent (ThermoScientific, Rockford, IL) and the BioRad ChemiDoc XRS+ system with a CCD 
camera and ImageLab software (BioRad, Hercules, CA). The protein band intensity from the 
resulting image was quantified using the ImageLab software. The amount of FGF19 was 
normalized to Diet1 protein levels. Western blot images shown in Fig. 6A were adjusted and 
cropped in Adobe Photoshop. 
Diet1/FGF19 co-immunoprecipitation. Protein co-immunoprecipitation was performed as 
previously described (7). HEK293T cells were transfected as described for the FGF19 secretion 
assay. After 48 hours, cells were lysed in PBS containing 1% NP-40 (Sigma, St. Louis, MO), 1X 
Complete Mini Protease Inhibitor Cocktail (Roche, Indianapolis, IN), and 0.1% phosphatase 
inhibitors 2 and 3 (Sigma, St. Louis, MO). Cell lysates were incubated overnight at 4°C with 1 
µg of mouse anti-V5 antibody (Life Technologies, Grand Island, NY), 4 µg of mouse anti-Myc 
antibody (Millipore, Billerica, MA), or 4 µg non-specific mouse IgG (Jackson ImmunoResearch, 
West Grove, PA). Protein A/G PLUS agarose beads (Santa Cruz Biotechnologies, Paso Robles, 
CA) were added for 3 hours at 4°C. After three washes with 1X PBS + 0.1% NP-40, protein was 
eluted from the beads with 1X loading buffer and 1% β-mercaptoethanol, boiled for 5 minutes, 
and analyzed by Western blot as described in the preceding section.  
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Statistical analysis. Fisher’s Exact tests and one-way analysis of variance were performed using 
VasserStats (http://www.vassarstats.net/). Two-way analysis of variance was performed using 
NCSS or GraphPad Prism. Linear regressions were performed with WinStat for Excel. Pair-wise 
comparisons were made using Student’s t-test.  
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RESULTS 
Generation of Diet1–/– C57BL/6J mice  
We previously identified the Diet1 gene in the C57BL/6ByJ mouse strain, which carries a 
naturally occurring mutation leading to a null allele for Diet1 (7). Since the C57BL/6ByJ mouse 
strain is >99% genetically identical to C57BL/6J mice, the latter strain was previously used as 
the wild-type control in studies of Diet1 (7, 8, 39, 40). However, to ensure that all effects of 
Diet1 deficiency can be attributed to the Diet1 null mutation (and not influenced by C57BL/6ByJ 
and C57BL/6J variation at loci other than Diet1), we generated a congenic strain by breeding the 
Diet1 null allele onto the C57BL/6J background for 8 generations. As expected, the resulting 
C57BL/6J Diet1–/– mice have undetectable Diet1 mRNA expression in the ileum (Fig. 1A).  
We assessed the C57BL/6J Diet1–/– mice for traits originally observed in the 
C57BL/6ByJ mice (7) and found that the effects on bile acid metabolism are recapitulated. Data 
shown are for mice fed a short-term (3 week) atherogenic diet, which enhances the phenotypic 
differences between wild-type and Diet1–deficient mice (8). As observed previously for 
C57BL/6ByJ mice (7, 8, 39), C57BL/6J Diet1–/– mice exhibit approximately 2-fold lower plasma 
cholesterol and lipoprotein levels, and >4-fold higher plasma bile acid levels, than Diet1+/+ mice  
(Fig. 1B, C). Intestinal gene expression is altered in the congenic strain similarly to C57BL/6ByJ 
mice, with dramatically reduced Fgf15 mRNA and increased Asbt mRNA (Fig. 1D). Diet1 
deficiency in C57BL/6ByJ mice does not influence hepatic Fgfr4 gene expression, and increases 
the expression of cholesterol synthetic genes (Cyp27, Cyp7a1, Cyp8b1) (8).  C57BL/6J Diet1–/– 
mice similarly exhibit wild-type Fgfr4 and elevated Cyp27 levels, but effects on Cyp7a1 and 
Cyp8b1 exhibit biological variability (Suppl. Fig. 1A). Thus, the plasma and intestinal 
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phenotypes originally observed in C57BL/6ByJ mice are present in Diet1–deficient C57BL/6J 
mice.  
 
Diet1 deficiency causes intestinal diarrhea in the mouse 
We hypothesized that Diet1 is required for normal gastrointestinal function, and assessed 
intestinal motility and presence of diarrhea (Fig. 2A). Diet1–/– mice exhibit normal food and 
water intake and body weight while eating an atherogenic diet (Fig. 2B; Suppl. Fig. 1B). 
However, Diet1–/– mice have reduced transit time of an intragastric bolus through the intestinal 
tract (Fig. 2C), indicating increased intestinal motility (16, 21, 30). The increase in intestinal 
motility in conjunction with increased bile acid levels in feces (8), raised the possibility that 
these animals may experience bile acid diarrhea. We assessed the intestinal content of water and 
solids after acute feeding the atherogenic diet for 3 hours (see scheme in Fig. 2A). Small and 
large intestine were collected, and intestinal contents extruded and weighed. Following 
evaporation, the weight difference in intestinal contents was used to calculate the content of 
water and of solids. Diet1–/– mice had increased water content of both small and large intestine 
per unit of intestinal length, indicating diarrhea (Fig. 2D, E). Increased water content was also 
observed in the small intestine of Diet1–/– mice when determined in fasted mice (Suppl. Fig. 1C). 
By contrast, the intestinal solids content was not affected by Diet1 (Fig. 2D, E), suggesting a 
secretory diarrhea in Diet1–/– mice. The elevated bile acid levels, increased gastrointestinal 
motility, and increased intestinal water content in the absence of alterations in dry content 
suggest parallels between Diet1–/– mice and patients with bile acid diarrhea.  
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Genetic variation in mouse Diet1 expression positively correlates with Fgf15 mRNA levels, 
and negatively with biliary bile acid and cholesterol levels 
Our data thus far indicate that complete deficiency of Diet1 influences Fgf15 mRNA, and plasma 
bile acid and cholesterol levels [Fig. 1; (7, 8)]. We wondered whether more modest, naturally 
occurring variations in Diet1 expression levels across different genetic backgrounds would also 
correlate with these traits. To assess this, we analyzed Diet1 and Fgf15 mRNA levels in ileum, 
biliary cholesterol levels, and bile acid levels across 76 inbred mouse strains, which comprise the 
Hybrid Mouse Diversity Panel (33). We observed a positive correlation between Diet1 and Fgf15 
expression levels, and a negative correlation between Diet1 mRNA and both bile acid and 
cholesterol levels in gall bladder (Fig. 3). These results strengthen the relationship between Diet1 
expression levels and these parameters, and indicate that small variations in Diet1 expression 
levels are associated with differences in Fgf15 mRNA, bile acid, and cholesterol levels.  
 
Sequence Variation in DIET1 
As a recently annotated gene, DIET1 probes were not available in existing exome sequencing 
platforms when we began our study, and DIET1 has not been resequenced in any disease cohort. 
To evaluate the potential role of rare or common DIET1 variants in primary BAD, we sequenced 
the complete DIET1 coding region and exon/intron junctions in a case-control cohort (22 cases, 
22 controls). The basic characteristics of the cohort are summarized in Table 1. Primary BAD 
cases were defined as individuals with very low SeHCAT retention levels (<7.3%), and controls 
were randomly selected from patients with normal bowel habits (38). 
We observed a total of 34 variants distributed along the length of DIET1 (Fig. 4). Of 
these, 25 produce nonsynonymous amino acid substitutions, including two novel single 
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nucleotide variants (SNVs) observed in single individuals from the Case group, one novel SNV 
observed in single individuals from the Control group, and a frame-shift mutation at position 
1221 detected in a single control subject (Suppl. Fig. 2, Suppl. Tables II and III). Since these 
variants occurred at low frequency, there was no statistical evidence of an enrichment of rare 
variants in the primary BAD cases, and we did not pursue these variants further.  
 
A common DIET1 variant with skewed frequency distribution between primary BAD case 
and control subjects 
Among the non-synonymous variants identified in DIET1, one previously recorded common 
variant (rs12256835, 5163 T>G; minor allele frequency 0.125) was present at statistically 
different levels in BAD cases and controls (Fisher’s Exact Test: nominal p = 0.0005; adjusted for 
multiple testing, p = 0.0175) (Suppl. Table III). The rs12256835 major allele encodes a histidine 
residue at position 1721 of the Diet1 protein (Fig. 4), and the minor allele encodes a glutamine 
residue (H1721Q). The minor (Q) allele was detected exclusively in control samples (11 of 44 
alleles). This polymorphism has a frequency of 0.3181 in dbSNP (build 150), suggesting that it is 
a common source of structural variation in the Diet1 protein in the general population. Based on 
existing database information from dbSNP, the allele frequency for rs12256835 is similar in 
European and East Asian populations (MAF 0.17–0.25, respectively), but deviates substantially 
in African populations (MAF 0.63). However, individuals of African descent were not present in 
our study sample, and cannot account for the difference in rs12256835 allele frequency that we 
observed between BAD cases and controls. 
 We investigated the association of rs12256835 genotype with BAD in an additional 78 
individuals, for an extended sample of 122 individuals (see Table 1 for characteristics of the 
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initial group, the extended group, and the total cohort). The individuals with primary BAD 
(defined as SeHCAT ≤ 10%) were more likely to have the T allele than the G allele (Fisher’s 
Exact Test: p = 0.035; Table 2). The reduced frequency of the minor allele (G) in those with 
primary BAD in the extended sample group was consistent with our observations in the initial 
cohort. 
 Walters and colleagues previously established a positive relationship between percent 
SeHCAT retention and FGF19 levels (28). To extend our analysis of the rs12256835 genotype 
association with BAD, we determined fasting FGF19 levels in the group of 78 patients described 
above. The cohort was separated into BAD cases (SeHCAT ≤ 10%) and controls (SeHCAT > 
10%), and classified according to the genotype at rs12256835 (TT vs. TG and G/G). FGF19 
values were significantly different between BAD cases and controls (p = 0.0088; two-way 
ANOVA), and there was a significant interaction between rs12256835 genotype and BAD 
case/control status (p = 0.016; Table 3). Post-hoc Student’s t-tests showed that in BAD cases, 
FGF19 levels were significantly lower in those with the T/T genotype compared to those with 
one or more G alleles (p = 0.0488, Table 3).  
 
The Diet1 H1721Q variant influences FGF19 production 
The data described above suggested that the Diet1 protein variants encoded by the two alleles at 
rs12256835 may have functional differences. The Diet1 protein has a predicted modular 
structure, with repeating interspersed LDL receptor and MAM (meprin/A5-protein/PTPmu) 
domains (7). The H1721Q amino acid change occurs at the transition between the seventh LDL 
receptor domain and the adjacent MAM domain (Fig. 4). We previously demonstrated that Diet1 
influences bile acid levels by modulating FGF15 or FGF19 production in mouse intestine and in 
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a human intestinal cell line, respectively (7). We also observed partial co-localization of Diet1 
and FGF19 in cultured enterocytes, and demonstrated that the proteins co-immunoprecipitate (7). 
We therefore assessed whether the Diet1 H and Q variants differ in ability to bind FGF19 and/or 
to promote FGF19 secretion.  
To assess whether the H-to-Q substitution alters Diet1/FGF19 protein interaction, we co-
expressed epitope-tagged Diet1 and FGF19 in cultured cells, immunoprecipitated the protein 
complex, and quantified the amount of each Diet1 isoform pulled down by FGF19. Expression of 
the 1721H and 1721Q Diet1 variants at similar levels (see “Lysate” lanes in Fig. 5) led to the 
pull-down of a similar proportion of Diet1 by immunoprecipitation of FGF19 (black boxes in 
Fig. 5). Thus, the two Diet1 isoforms interact with FGF19 similarly.  
To assess the ability of the two Diet1 protein variants to promote FGF19 protein 
secretion, we co-expressed V5-tagged Diet1-1721H or -1721Q with Myc-tagged FGF19 in 
HEK293T cells (Fig. 6A, B). Cells were collected 48 hours after transfection to quantify 
intracellular FGF19, and medium was collected during the final 24 hours to quantify secreted 
FGF19. FGF19 was quantified by Western blot analysis and normalized to the amount of Diet1 
protein expressed (Fig. 6B) as well as to actin levels (Suppl. Fig. 3). As a control for specificity 
of the Diet1 effect, we analyzed the levels of FGF19 secretion in response to expression of an 
irrelevant protein with a similar molecular weight to Diet1 (Kdm5c-V5). A representative 
experiment (from a total of 9 individual experiments) is shown in Fig. 6A. The presence of 
Diet1–1721H or –1721Q protein increased FGF19 production compared to the control protein. 
The amount of intracellular FGF19 was similar for the 1721H or 1721Q Diet1 variants, but the 
amount of FGF19 secreted into the culture medium in 24 hours was greater for Diet1–1721Q 
than Diet1–1721H (Fig. 6A, B and Suppl. Fig. 3). This relationship was confirmed in the meta-
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analysis of 9 independent experiments (each performed in triplicate or quadruplicate). The 
Diet1–1721Q variant enhanced FGF19 secretion by approximately 70% compared to Diet1–
1721H (Fig. 6B; p < 0.01). By contrast, another Diet1 variant identified in our study and located 
in the same protein domain (D1712G) did not affect FGF19 secretion (Fig. 6C and D). Thus, it 
appears that the differential effect of the 1721H and 1721Q Diet1 proteins on FGF19 secretion is 
related to the specific amino acid substitution.  
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DISCUSSION 
The current study expands our understanding of Diet1 deficiency on intestinal function and 
assesses the effects of Diet1/DIET1 genetic variation on traits related to FGF15/19 and bile acid 
metabolism. We evaluated a new Diet1–/– mouse strain on a C57BL/6J background in 
comparison to isogenic C57BL/6J wild-type mice (in contrast to the previous studies comparing 
C57BL/6ByJ mice, which carry the natural Diet1 null allele, to C57BL/6J mice). The Diet1–/– 
C57BL/6J mice recapitulated previous phenotypes in intestinal gene expression, as well as 
plasma lipid and bile acid levels (7, 8). We also found that Diet1 deficiency increases 
gastrointestinal transit time and intestinal water content, which, together with elevated bile acid 
levels and reduced FGF15 levels, parallel primary BAD in humans. The increased intestinal 
water content is not apparent when Diet1–/– mice are fed a standard chow diet (unpublished data), 
suggesting that elevated circulating bile acid levels that are stimulated by short-term atherogenic 
diet contribute to diarrheal phenotype, as is seen in patients with bile acid diarrhea.   
In addition to effects of the extreme genetic condition of Diet1 deficiency, we assessed 
whether modest, naturally occurring variations in Diet1 influence traits that are affected in Diet1–
/– mice. We found that genetic variation in Diet1 intestinal mRNA expression across a panel of 
76 inbred mouse strains correlates positively with Fgf15 mRNA levels, and negatively with and 
bile acid and cholesterol levels. These results underscore that small changes in Diet1 mRNA 
levels (such as might occur among individuals in the human population) influence Fgf15 
expression levels, as well as bile acid and cholesterol levels. In the future, it will be interesting to 
determine whether the genetic variations in Diet1 expression levels are associated with cis-acting 
regulatory sequence variants that differ across mouse strains.  
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The phenotype of Diet1–/– mice led us to investigate whether DIET1 genetic variation 
influences the severity of BAD in humans. We identified a prevalent (minor allele frequency of 
approximately 30% across populations) non-synonymous variant in the DIET1 coding region 
that is associated with SeHCAT retention levels in BAD patients and which alters levels of 
FGF19 secretion in cultured cells. Previous genetic studies of primary BAD have focused on a 
few candidate genes with established roles in bile acid metabolism. A rare mutation in 
SLC10A2/ASBT was identified in one family with congenital BAD, but variations in SLC10A2 
appear not to be associated with adult-onset primary BAD (41, 42). Since DIET1 was not 
annotated until recently (7), this gene is not represented on existing expression microarrays nor 
exome sequencing platforms, and little gene expression or sequence data are available for this 
gene in human samples. Our DIET1 resequencing identified several rare non-synonymous amino 
acid substitutions and a frame-shift mutation. One common DIET1 variant (rs12256835), which 
alters amino acid composition (H1721Q), was significantly associated with BAD status.  
We found that Diet1-1721Q protein promotes increased FGF19 levels in the medium in a 
cultured cell assay system compared to Diet1-1721H. This effect is likely due to the specific 
position and amino acid alteration, as a D1712G non-conservative substitution that is located 
only 9 amino acids away had no effect on FGF19 secretion. A full understanding of the role of 
residue 1721 in Diet1 protein function will require additional protein structure-function studies. 
An attractive hypothesis is that H1721Q amino acid change affects Diet1 protein conformation 
and/or interactions with other cellular proteins, potentially affecting FGF19 trafficking and 
secretion.  
Our findings raise the possibility that the Diet1 H1721Q variant could contribute to the 7-
fold variation in plasma FGF19 levels that have been observed in healthy individuals (11, 43). 
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Resequencing DIET1 in additional subjects will be required to reveal whether DIET1 rare 
mutations or additional common variants contribute to variations in bile acid metabolism.  
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TABLES 
 
Table 1. Clinical characteristics of BAD case/control cohorts. 
 Group 1 Group 2 All subjects 
N 44 78 122 
Age range (years) 27-80 17-90 17-90 
Male : Female 13 : 31 34 : 43 47 : 74 
SeHCAT retention range 0.5-7.3%a 0.4-90% 0.4-90% 
a Non-BAD subjects were not assessed for % SeHCAT retention 
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Table 2. Allele frequencies for rs12256835 in all subjects. 
The number of T and G alleles genotyped in 122 subjects are shown, segregated as BAD cases 
(SeHCAT ≤ 10%) and controls (SeHCAT > 10%). The third column lists the p-value of 
association as calculated by Fisher’s Exact Test, and the Odds Ratio (with 95% confidence 
intervals indicated) is given in the final column. 
 
 T Allele G allele p-value 
Odds Ratio 
(95% CI) 
SeHCAT ≤ 10% 83 13 
0.035 
0.470 
(0.235, 0.940) SeHCAT > 10% 111 37 
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Table 3. rs12256835 genotype and FGF19 levels 
Fasting FGF19 levels for a cohort of 78 patients are shown, segregated as BAD cases (SeHCAT 
≤ 10%) and controls (SeHCAT > 10%) and classified according to the genotype at rs12256835. 
FGF19 values were log-normalized before statistical analysis. FGF19 values were significantly 
different between BAD cases and controls p = 0.0088 (two-way ANOVA), and there was a 
significant interaction between rs12256835 genotype and BAD case/control status (p = 0.016). 
Post-hoc Student’s t-tests confirmed lower FGF19 levels in those with primary BAD carrying the 
T/T genotype (indicated by *, p < 0.05).  
 
  
FGF19 (pg/ml) 
T/T T/G & G/G 
SeHCAT ≤10% 
Mean ± SEM 119 ± 19* 253 ± 56 
n 14 12 
SeHCAT >10% 
Mean ± SEM 246 ± 24 215 ± 28 
n 30 22 
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FIGURE LEGENDS 
 
Figure 1. Altered bile acid, cholesterol, and ileal gene expression levels in C57BL/6J Diet1–/–
mice.  
(A) Confirmation of Diet1 deficiency in C57BL/6J Diet1–/– mouse ileum. N = 5-7 
mice/genotype, as indicated. *, p < 0.05; **, p < 0.01; ***, p < 0.001 by Student’s t-test. 
(B) Reduced plasma total, HDL, and V/LDL cholesterol levels in C57BL/6J Diet1–/– compared 
to isogenic Diet1+/+ mice fed an atherogenic diet 3 weeks. **, p < 0.01 and ***, p < 0.001 on 2-
way ANOVA. 
(C) Elevated plasma bile acid levels in C57BL/6J Diet1–/–mice fed an atherogenic diet for 3 
weeks.   
(D) Reduced ileal Fgf15 and elevated Asbt expression in C57BL/6J Diet1–/–mice fed an 
atherogenic diet 3 weeks.  
 
Figure 2. Diet1–/– mice exhibit reduced gastrointestinal transit time and diarrhea.  
(A) Study design to measure gastrointestinal transit time and diarrhea. Mice were fed an 
atherogenic diet for two weeks and gastrointestinal transit time measured after gastric 
administration of a bolus containing dye. Time to first fecal pellet was determined. Diarrhea was 
assessed in fed animals by quantifying small and large intestine water and solid contents 
(described further in Methods).  
(B) Diet1–/– and Diet1+/+mice have similar body weight after two weeks on atherogenic diet. N = 
6–9. Statistical analyses via Student’s t-test. *, p < 0.05.  
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(C) Diet1–/– mice exhibit reduced total gastrointestinal transit time, indicating increased intestinal 
motility.  
(D) Small intestinal (SI) water content is increased in Diet1–/– mice when expressed as absolute 
amount and when normalized to intestinal length. There were no differences in SI solids content 
between genotypes.   
(E) Large intestine (LI) water content normalized to length is increased in Diet1–/– mice. There 
were no differences in LI solids content between genotypes.  
 
Figure 3. Diet1 mRNA levels correlate positively with Fgf15 mRNA, and negatively with 
biliary bile acid and cholesterol levels across 76 mouse strains. Diet1 mRNA levels in ileum 
vary across 76 inbred mouse strains, and correlate positively with Fgf15 mRNA levels. Diet1 
mRNA levels correlate negatively with bile acid and cholesterol levels in bile collected from the 
gall bladder. Each point on graphs represents a single mouse strain (3-5 mice/strain) from the 
Hybrid Mouse Diversity Panel (see Methods). Mice were fed a standard chow diet.  
 
Figure 4. Location of nonsynonymous variants in human Diet1 protein. 
Schematic of Diet1 protein domain structure. Arrows above the diagram indicate the 25 
nonsynonymous variants and one single-nucleotide deletion detected in cases and controls. 
Arrows below the diagram indicate the novel nonsynonymous variants, the frame-shift mutation, 
and the position of rs12256835.  
 
Figure 5. Diet1–1721H and –1721Q isoforms do not differentially affect Diet1-FGF19 
interaction. 
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Co-immunoprecipitation of Diet1–1721H and Diet1–1721Q with FGF19. FGF19-Myc was co-
expressed in HEK293T cells with Diet1–1721H-V5 or Diet1–1721Q-V5. Input lanes show 
similar levels of expression of the two Diet1 isoforms. Bands corresponding to precipitation of 
FGF19 with Diet1–1721H are on the left of the dashed line, and with Diet1–1721Q are on the 
right. Dashed boxes indicate immunoprecipitation of Diet1 (V5 IP); solid boxes indicate 
immunoprecipitation of FGF19 (Myc IP). Both Diet1 isoforms interact with FGF19 with similar 
efficiency. A representative blot from 8 experiments is shown. 
 
Figure 6. DIET1 variant rs12256835 influences secretion of FGF19 in a cell-based assay. 
(A) Representative results of an FGF19 secretion assay comparing Diet1-1721H and 1721-Q. 
FGF19-Myc was expressed in HEK293T cells in combination with either Diet1–1721H-V5, 
Diet1–1721Q-V5, or an irrelevant control protein (Kdm5c-V5). Cellular Diet1 protein levels and 
secreted FGF19 levels were visualized by Western blot. MW, molecular weight in kD. 
(B) Quantification of FGF19 secretion from 9 experiments of type shown in (A). Each point is 
one independent transfection (done in triplicate or quadruplicate), representing the amount of 
FGF19 secreted per unit of cellular V5 expression for control protein (Kdm5c), Diet1–1721H, or 
Diet1–1721Q. Overall p-value for all three conditions is p = 3.70 x 10-7 (one-way ANOVA). 
Individual comparisons were made using Tukey HSD post-hoc test on log2-normalized values. 
Small horizontal lines represent geometric mean of samples for each protein isoform; * p < 0.05, 
** p < 0.01. 
C) Representative results of an FGF19 secretion assay comparing Diet1-1721D and -1721G. 
Details as in (A).  
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D) Quantification of FGF19 secretion from 5 experiments of type shown in (C). No statistically 
significant difference in the amount of extracellular FGF19 was detected between Diet1–1712D 
and –1712G (p = 0.945; one-way ANOVA).  
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